The vaccine, developed by Astrazenka in collaboration with Oxford University, has shown promising results among young and old experimenters alike, following mass trials.
Astra Zenka's vaccine // Photo: Reuters
Good news from the fight against coronary heart disease in the UK: A senior official at Astrazenka told the country's media that the main doses of the vaccine developed by the company, along with the prestigious Oxford University, will be given to medical staff in the country before Christmas.
In an interview with the British Daily Mail, Professor Adrian Hill, head of the Jenner Institute at Oxford University, reveals the vast array set up by Astrazenka to ensure that the vaccine reaches large markets in the UK and around the world: "Ten large factories around the world "Billions of vaccine doses are being produced ahead of the vaccine approval. I would be surprised with the epidemic not starting its way down in the spring months, at least in the UK."
Hill added that preparing vaccine doses for medical teams in the UK before Christmas was a difficult challenge, but company staff met it and the general public vaccination in the UK could begin with the spread of 2021. More than 10,000 volunteers in the UK alone, in addition to thousands more in Brazil and South Africa, already Received the vaccine as part of the final phase of the trial.
Despite the vaccine of the pharmaceutical company Astrazenka has not yet received the necessary necessary medical approvals, the company today announced a major leap forward in the vaccine trial as the data showed that elderly volunteers who received the vaccine developed antibodies at the required level.
This is great news as the elderly are the population most at risk from corona disease and giving them priority in the vaccine will allow a faster return to routine.
"It is very encouraging for us to see that the response of the immune system was the same between young adults and older adults and that there were no unusual reactions among adults, who tend to get the disease more severely. The results are an addition to the body of evidence that we are developing," said Dover. Astrazenka company to the Reuters news agency.
Last month, Astrazenka suffered a severe blow to her vaccination program when it was learned that one of the recipients of the experimental vaccine had developed alarming symptoms.
The company stopped the whole trial procedure for a week and it was a month after the company came to the conclusion that further vaccine development is safe.